...
首页> 外文期刊>The Journal of Antibiotics: An International Journal >Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors
【24h】

Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors

机译:发现一种可杀死非复制型结核分枝杆菌的卡普拉霉素类似物及其与转位酶I抑制剂的协同作用

获取原文
获取原文并翻译 | 示例
           

摘要

Capuramycin (1) and its analogs are strong translocase I (MurX/MraY) inhibitors. In our structure-activity relationship studies of capuramycin analogs against Mycobacterium tuberculosis (Mtb), we observed for the first time that a capuramycin analog, UT-01320 (3) killed nonreplicating (dormant) Mtb at low concentrations under low oxygen conditions, whereas selective MurX inhibitors killed only replicating Mtb under aerobic conditions. Interestingly, 3 did not exhibit MurX enzyme inhibitory activity even at high concentrations, however, 3 inhibited bacterial RNA polymerases with the IC50 values of 100-150 nM range. A new RNA polymerase inhibitor 3 displayed strong synergistic effects with a MurX inhibitor SQ 641 (2), a promising preclinical tuberculosis drug.
机译:Capuramycin(1)及其类似物是强转位酶I(MurX / MraY)抑制剂。在我们的卡普拉霉素类似物抗结核分枝杆菌(Mtb)的结构-活性关系研究中,我们首次观察到卡普拉霉素类似物UT-01320(3)在低氧条件下以低浓度杀死了非复制型(休眠)Mtb,而选择性MurX抑制剂在有氧条件下仅杀死复制的Mtb。有趣的是,即使在高浓度下,也有3个没有表现出MurX酶抑制活性,但是,有3个抑制了细菌RNA聚合酶,IC50值为100-150 nM。一种新型的RNA聚合酶抑制剂3与有希望的临床前结核病药物MurX抑制剂SQ 641(2)表现出强大的协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号